Jasper Therapeutics

Jasper Therapeutics (operating at jaspertx.com) is a clinical-stage biotechnology company pioneering treatments for chronic mast cell diseases. Founded in 2019 and headquartered in Redwood City, CA, Jasper Therapeutics is redefining therapeutic approaches for conditions driven by dysregulated mast cells, which play a critical role in allergic and inflammatory reactions. Unlike conventional treatments that merely manage symptoms, Jasper’s lead candidate, briquilimab, targets mast cell apoptosis—a novel mechanism designed to induce lasting remission. This approach leverages an anti-KIT antibody to directly address the root cause of disease, offering patients a potential path to safer, more effective therapies. The company’s work is backed by $50 million in funding across three rounds, enabling its clinical-stage development pipeline. By focusing on mast cell biology, Jasper Therapeutics aims to transform outcomes for patients suffering from debilitating chronic conditions, where current treatments often fall short.